Are the IRBs prioritizing reviews of submissions?

Yes. We are doing additional triage of all submissions (except continuing reviews) and prioritizing as follows:

• Initial reviews:
  • FDA treatment protocols (HDEs, e-uses)
  • COVID studies (see below)
  • Potentially therapeutic clinical trials
  • Applications with funding approval needs

• Changes of protocol:
  • COVID-related changes
  • Safety-related changes
  • Changes to potentially therapeutic studies
  • Funding changes

• Reportable events
  • COVID-related reports take priority

If you have urgent review needs not covered above, please contact the following:

• For HS/MR IRBs, please email irbdirector@hsirb.wisc.edu
• For the ED/SBS IRB, please email arrow-help@mailplus.wisc.edu